Skip to main content
SpringerLink
Log in

Prevention of Acute Cisplatin-Induced Nausea and Vomiting

  • Conference paper
Antiemetics in the Supportive Care of Cancer Patients

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

Abstract

All cytotoxic drugs can induce nausea and vomiting depending on the type of agent, dose, route and schedule of administration [1]. This variability underlines the differences in mechanisms responsible for the difference in onset and duration of this side-effect. Cisplatin is one of the most widely used cytotoxic agents and has significantly contributed to the curative potential of chemotherapy. However, the spectrum of side-effects is substantial and its capacity to induce nausea and vomiting is unprecedented. High doses of cisplatin produce acute nausea and vomiting in almost all patients unless antiemetic drugs are used. Therefore much effort has been made to control this distressing side-effect and the present status will be updated in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Seynaeve C, de Mulder PHM, Verweij J, Gralla RJ: Controlling cancer chemotherapy-induced emesis. An update. Pharm Weekbl [Sci] 1991 (13):189–197

    Article  CAS  Google Scholar 

  2. Allen SG, Smith SF: Small intestinal toxicity of cisplatin — comparison of effects of platinum analogues and dexamethasone. Br J Cancer 1986 (53):355–360

    Article  Google Scholar 

  3. Akwari OE: The gastrointestinal tract in chemotherapy induced emesis. Drugs 1983 (25):18–34

    Article  PubMed  CAS  Google Scholar 

  4. Schwörer H, Racke K, Kilbinger H: Cisplatin increases the release of 5-hydroxytryptamine from the isolated vascularly perfused small intestine of the guinea pig: Involvement of 5HT3 receptors. Naunyn-Schmiedeberg’s Arch Pharmacol 1991 (344):143–149

    Article  Google Scholar 

  5. Miner WD, Sanger G: Inhibition of cisplatin induced vomiting by selective 5-hydroxytryptamine M-receptor antoganism. Br J Parmacol 1986 (88):497–499

    CAS  Google Scholar 

  6. Gralla RJ, Itri LM, Pisko SE et al: Antiemetic efficacy of high-dose metoclopramide: randomised trials with placebo and prochlorperazine in patients with chemotherapy induced nausea and vomiting. N Engl J Med 1981 (305):905–909

    Article  PubMed  CAS  Google Scholar 

  7. Craig JB, Powell BL: Review: The management of nausea and vomiting in clinical oncology. Am J Med Sci 1987 (293): 34–44

    Article  PubMed  CAS  Google Scholar 

  8. Grunberg SM, Gala KV, Lampenfield M et al: Comparison of the antiemitic efficacy of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in randomized double-blind crossover study. J Clin Oncol 1984 (2):782–787

    PubMed  CAS  Google Scholar 

  9. Sailer R, Hellenbrecht D: High doses of metoclopramide or droperidol in the prevention of cisplatin induced emesis. Eur J Cancer Clin Oncol 1986 (22):1199–1203

    Article  Google Scholar 

  10. Basurto C, Roila F, Del Favero A: A prospective randomised double blind crossover study comparing the antiemetic effect of alizapride and metoclopramide in patients receiving cisplatin chemotherapy. Cancer Invest (1988):475–479

    Google Scholar 

  11. Sailer R, Hellenbrecht D: Comparision of the antiemetic efficacy of 2 high-dose benzamides, metoclopramide and alizapride, against cisplatin induced emesis. Cancer Treatm Rep 1985 (69): 1301–1302

    Google Scholar 

  12. Frustaci S, Grattoni E, Turnolo S et al: Randomised crossover antiemetic study in cisplatin treated patients. Cancer Chemother Pharmacol 1986 (17): 75–79

    Article  PubMed  CAS  Google Scholar 

  13. Meyer BR, Levin M, Draper DE et al: Optimising metoclopramide control of cisplatin induced emesis. Ann Intern Med 1984 (100):393–395

    PubMed  CAS  Google Scholar 

  14. Kerr PJ, Graham J, McGovern E et al: The relationship between steady state metoclopramide levels and control of emesis during treatment with cisplat-inum. Br J Clin Pharm 11985 (20):426–427

    Google Scholar 

  15. Mc Dermed JE, Cohen JL, Joseph C, Strum SB: Clinical pharmacokinetics of high-dose metoclopramide in cancer patients receiving cisplatin therapy. J Clin Oncol 1985 (3):1400–1408

    Google Scholar 

  16. Grundberg SM, Mc Dermed JE, Berstein L, Cohen JL: Examination of the correlation of serum MCP levels with antiemetic efficacy in patients receiving cisplatin. Cancer Chemoth Pharmac 1987 (20):332–336

    Google Scholar 

  17. Kris MG, Gralla RJ, Clark RA et al: Antiemetic control and prevention of side effects of anticancer therapy with lorazepam when used in combination with metoclopramide and dexamethasone. Cancer 1987 (60):2816–2822

    Article  PubMed  CAS  Google Scholar 

  18. Anthony L, Krozeby M, Woodward et al: Antiemetic effecacy of oral versus intravenous MCP in patients receiving cisplatin. J Clin Oncol 1985 (4):98–103

    Google Scholar 

  19. Warrington PS, Allan SG, Cornbleet MA, Mac-Pherson JS, Smyth JF, Leonard RCF: Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin. Br Med J 1986 (293): 1334–1337

    Article  CAS  Google Scholar 

  20. Parashos PJ, Dugan WM, Fry MW: Continuous infusion metoclopramide: clinical trials, pharmacokinetic considerations and cost effectiviness. In: Engstrom PF, Mortenson LE, Anderson PN (eds). Progress in Clinical and Biological Research. A. Liss, New York 1987 p 303

    Google Scholar 

  21. Agostinucci, WA, Gannon RH, Schauer PK, Walters JK: Continuous infusion of metoclopramide for prevention of chemotherapy induced emesis. Clin Pharmacology 1986 (5): 150–153

    CAS  Google Scholar 

  22. Navari RM: Comparision of intermittent versus continuous infusion metoclopramide in control of acute nausea induced by cisplatin chemotherapy. J Clin Oncol 1989 (7): 943–946

    PubMed  CAS  Google Scholar 

  23. Tyson LB, Gralla RJ, Kris MG, Young CW, Clark RA: Dose-ranging antiemetic trial of high-dose oral MCP. Am J Clin Oncol (1989):239–243

    Google Scholar 

  24. Anthony L, Krozeby M, Woodward et al: Antiemetic efficacy of oral versus intravenous MCP in patients receiving cisplatin. J Clin Oncol 1985 (4):98–103

    Google Scholar 

  25. Allan SG, Cornbleet MA, Warrington PS et al: Dexamethasone and high dose metoclopramide: Efficacy in controlling cisplatin-induced nausea and vomiting. Br Med J 1984 (289):878–879

    Article  CAS  Google Scholar 

  26. Roseli R, Abad-Esteve A, Ribas-Mundo M et al: Evaluation of a combination antiemetic regimen including i.v. high-dose metoclopramide, dexamethasone, and diphenhydramine in cisplatin-based chemotherapy regimens. Cancer Treat Rep 1985 (69):909–910

    Google Scholar 

  27. Roila F, Tonato M, Basurto C et al: Antiemetic activity of high dose of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients. J Clin Oncol 1987 (5): 141–149

    PubMed  CAS  Google Scholar 

  28. Cognetti F, Carlini P, Pinnaro P et al: Maintenance of antiemetic effect of a MCP/Dex combination during subsequent cisplatin courses. Oncology 1986 (43): 292–294

    Article  PubMed  CAS  Google Scholar 

  29. Aapro MS: Present role of corticosteroids as antiemetics. In: Senn H-J and Glaus A (eds) Recent Results in Cancer Research. Springer-Verlag, Berlin Heidelberg 1991 pp 91–100

    Google Scholar 

  30. Kearsley JH, Williams AM, Fiumara AM: Antiemetic superiority of lorazepam over oxazepam and methylprednisolone as premedicants for patients receiving cisplatin-containing chemotherapy. Cancer 1989 (64): 1595–1599

    Article  PubMed  CAS  Google Scholar 

  31. Bishop JF, Olver IN, Wolf MM et al: Lorazepam: a randomised, double-blind, crossover study of a new antiemetic in patients receiving cytotoxic chemotherapy and prochlorperazine. J Clin Oncol 1984 (2): 691–695

    PubMed  CAS  Google Scholar 

  32. Gordon CJ, Pasdur R, Zicarelli A, Cummings G, Al-Sarraf M: Metoclopramide versus metoclopramide and lorazepam. Cancer 1989 (63):578–582

    Article  PubMed  CAS  Google Scholar 

  33. Kriss MG, Gralla RJ, Tyson LB et al: Improved control of cisplatin induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone and diphenhydramine. Cancer 1985 (55):527–534

    Article  Google Scholar 

  34. Seynaeve C, Verweij J, de Mulder PHM: 5 HT3 receptor antagonists. A new approach in emesis. A review of ondansetron, granisetron and tropisetron. Anti Cancer Drugs 1991 (19):203–208

    Google Scholar 

  35. Tyers MB, Freeman AJ: Mechanism of the antiemetic activity of 5-HT3 receptor antagonists. Oncology 1992 (49):263–268

    Article  PubMed  CAS  Google Scholar 

  36. Andrew PLR, Bhandari P, Davey PT, Bingham S, Marr HE, Blower PR: Are all 5-T3 receptor antagonists the same? Eur J Cancer 1992 (28A suppl 1): s2–s6

    Article  Google Scholar 

  37. Aapro MS: ‘... Setron’?: Are 5-HT3 receptor antagonists different? Eur J Cancer 1993 (29a):1655

    Article  PubMed  CAS  Google Scholar 

  38. Perez EA: Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 1995 (13):1036–1043

    PubMed  CAS  Google Scholar 

  39. De Haan LD, de Mulder PHM, Beex LVAM et al: The efficacy of GR38032F, an antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting. Eur J Cancer Clin Oncol 1988 (24):1383–1384

    Article  PubMed  Google Scholar 

  40. Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion N, Pujade-Lauraine E, Paule B, Paes D, Bons J: Comparision of the 5-hydroxytryptamine, (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990 (322): 816–821

    Article  PubMed  CAS  Google Scholar 

  41. De Mulder PHM, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Lane Allman E, Beranek P, Verweij J: Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990 (113):834–840

    PubMed  Google Scholar 

  42. Kris MG, Gralla RJ, Clark RA, Tyson LB: Dose-ranging evaluation of the serotonin antagonist GR38032F when used as an antiemetic in patients recieving anticancer therapy. J Clin Oncol 1988 (6):659–662

    PubMed  CAS  Google Scholar 

  43. Grundberg SM, Stevenson LL, Russell CA, McDermed JE: Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1989 (7):1137–1141

    Google Scholar 

  44. Kris MG, Gralla RJ, Clark RA, Tyson LB: Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. JNCI 1989 (81):42–46

    PubMed  CAS  Google Scholar 

  45. Hesketh PJ, Murphy WK, Lester EP et al: GR38032F: a novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol 1989 (7):700–705

    PubMed  CAS  Google Scholar 

  46. Khojasteh A, Sartiano G, Tapazoglou E et al: Ondansetron for the prevention of emesis induced by high-dose cisplatin. Cancer 1990 (66):1101–1105

    Article  PubMed  CAS  Google Scholar 

  47. Hainsworth J, Harvey W, Pendergrass K et al: A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 1991 (9):721–728

    PubMed  CAS  Google Scholar 

  48. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL: Efficacy of ondansetron and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990 (322):810–816

    Article  PubMed  CAS  Google Scholar 

  49. Marty M, D’Allens H: Etude randomisée en double-insu comparant l’efficacité de l’ondansetron selon deux modes d’administration: injection unique et perfusion continue. Cahiers Cancer 1990 (2): 541–546

    Google Scholar 

  50. Seynaeve C, Schuller J, Buser K et al: Comparision. of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Br J Cancer 1992 (66):192–197

    Article  PubMed  CAS  Google Scholar 

  51. Ruff P, Paska W, Goedhals L et al: Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology 1994 (51):113–118

    Article  PubMed  CAS  Google Scholar 

  52. Beck Th M, Hesketh PJ, Madajewicz S et al: Stratified, randomized, double-blind comparision of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992 (10):1969–1975

    PubMed  CAS  Google Scholar 

  53. Roila F, Tonato M, Cognetti F et al: Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991 (9):675–678

    PubMed  CAS  Google Scholar 

  54. Smith DB, Newlands ES, Rustin GJS et al: Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet 1991 (338):487–490

    Article  PubMed  CAS  Google Scholar 

  55. Smyth JF, Coleman RE, Nicolson M et al: Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? Br Med J 1991 (303):1423–1426

    Article  CAS  Google Scholar 

  56. Italian Group for Antiemetic Research: Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. J Clin Oncol 1993 (11):2396–2404

    Google Scholar 

  57. Kris MG, Gralla RJ, Clark RA et al: Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. JNCl 1989 (81):42–46

    CAS  Google Scholar 

  58. Hainsworth JD: The use of ondansetron in patients receiving multiple-day cisplatin regimens. Sem Oncol 1992 (19 suppl 10):48–52

    CAS  Google Scholar 

  59. Sledge GW, Einhorn LH, Nagy C et al: Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 1992 (70):2524–2528

    Article  PubMed  Google Scholar 

  60. Fox SM, Einhorn LH, Cox E, Powell N, Abdy A: Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol 1993 (11):2391–2395

    PubMed  CAS  Google Scholar 

  61. Räth U, Upadhyaya BK, Arechavala E et al: Role of ondansetron plus dexamethasone in fractionated chemotherapy. Oncology 1993 (50):168–172

    Article  PubMed  Google Scholar 

  62. Upward JW, Arnold BDC, Link C et al: The clinical pharmacology of granisetron (BRL43694A), a novel specific 5-HT3 antagonist. Eur J Cancer 1990 (26 supp1):S12–S15

    PubMed  CAS  Google Scholar 

  63. Kamanabrou D, on behalf of the Granisetron Study Group: Intravenous granisetron — establishing the optimal dose. Eur J Cancer 1992 (28A suppl 1):S6–11

    Article  PubMed  Google Scholar 

  64. Soukop M, on behalf of the Granisetron Study Group: A comparison of two dose levels of granisetron in patients recieving high-dose cisplatin. Eur J Cancer 1990 (29 suppl 1):S15–S19

    Google Scholar 

  65. Chevallier B, on behalf of the Granisetron Study Group: The control of acute cisplatin-induced emesis — a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Br J Cancer 1993 (68):176–180

    Article  PubMed  CAS  Google Scholar 

  66. Bremer K, on behalf of the Granisetron Study Group: A single-blind study of the efficacy and safety of intravenous granisetron compared with alizapride plus dexamethasone in the prophylaxis and control of emesis in patients receiving 5-day cytostatic therapy. Eur J Cancer 1992 (28A no 6/7): 1018–1022

    Article  PubMed  CAS  Google Scholar 

  67. Tyson LR, Gralla RJ, Kris MG, Clark RA: Phase I antiemetic study of the serotonin antagonist ICS 205–930. Proc Am Soc Clin Oncol 1989 (8):331

    Google Scholar 

  68. Stamatakis L, Michel J, Van Belle S et al: ICS 205–930: A dose finding study in the prevention of cisplatin induced nausea and vomiting. Proc Am Soc Clin Oncol 1989 (8):327

    Google Scholar 

  69. Krzakowski M, Madaj G, Pawinsky A et al: A comparative study of the use of Novaban, a 5-HT antagonist, versus a standard anti-emetic regimen of dexamethasone and metoclopramide in the treatment of chemotherapy-induced emesis. Ann Oncol 1992 (3):155–161

    Google Scholar 

  70. Kris MG, Tyson LB: Tropisetron (ICS 205–930): A selective 5-hydroxtryptamine antagonist. Eur J Cancer 1993 (29A suppl 1):30–32

    Article  Google Scholar 

  71. Noble A, Bremer K, Dilly SG et al: A double blind, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: Assessment of efficacy, safety, and patient preference. Eur J Cancer 1994 (30A): 1083–1088

    Article  PubMed  CAS  Google Scholar 

  72. Gebbia V, Cannata G, Testa A et al: Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer 1994 (74):1945–1952

    Article  PubMed  CAS  Google Scholar 

  73. Roila F, De Angelis V, Cognetti F et al: Ondansetron versus granisetron, both combined with dexamethasone in the prevention of cisplatin-induced emesis. Proc Am Soc Clin Oncol 1995 (14):523

    Google Scholar 

  74. Chaffee BJ, Tankanow RM: Drug Review. Ondansetron — the first of a new class of antiemetic agents. Clin Pharm 1991 (10):430–446

    PubMed  CAS  Google Scholar 

  75. Halperin JR, Murphy B: Extrapyramidal reaction on ondansetron. Cancer 1992 (69):1275

    Article  PubMed  CAS  Google Scholar 

  76. Jacobsen MBJ: Ondansetron in carcinoid syndrome. Lancet 1992 (340):185

    Article  PubMed  CAS  Google Scholar 

  77. Plosker GL, Goa KL: Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic. Drugs 1991 (42):805–824

    Article  PubMed  CAS  Google Scholar 

  78. de Bruijn KM: Tropisetron. A review of the clinical experience. Drugs 1992 (43):11–22

    Article  PubMed  Google Scholar 

  79. Herrstedt J, Sigsgaard T, Boesgaard M et al: Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 1993 (328):1076–1081

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Medical Oncology, University Hospital Nijmegen, Geert Grooteplein 8, 6500 HB, Nijmegen, The Netherlands

    Pieter H. M. De Mulder

  2. Department of Medical Oncology, Rotterdam Cancer Institute/Daniel den Hoed Cancer Centre, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands

    Jaap Verweij

Authors
  1. Pieter H. M. De Mulder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jaap Verweij
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical Oncology Division, Policlinico Monteluce, Via Brunamonti, 06122, Perugia, Italy

    Maurizio Tonato M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

De Mulder, P.H.M., Verweij, J. (1996). Prevention of Acute Cisplatin-Induced Nausea and Vomiting. In: Tonato, M. (eds) Antiemetics in the Supportive Care of Cancer Patients. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-80240-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-80240-9_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-80242-3

  • Online ISBN: 978-3-642-80240-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation